Clinical Trials Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Oct 6, 2022; 10(28): 10085-10096
Published online Oct 6, 2022. doi: 10.12998/wjcc.v10.i28.10085
Table 1 Hepatitis B virus DNA levels in chronic hepatitis B patients at weeks 168 and 192 (mean SD, log10IU/mL)
Group
HBeAg-positive
HBeAg-negative
Baseline
168 wk
192 wk
Baseline
168 wk
192 wk
A7.64 ± 1.011.18 ± 0.860.9 ± 0.966.22 ± 1.250.62 ± 0.660.35 ± 0.59
B7.65 ± 0.951.13 ± 0.821.02 ± 0.856.31 ± 1.370.36 ± 0.610.33 ± 0.57
P0.9370.7280.5600.7980.1500.867
Table 2 Reduction of hepatitis B virus DNA levels of chronic hepatitis B patients at weeks 168 and 192 (mean SD, log10IU/mL)
Group
HBeAg-positive
HBeAg-negative
168 wk
192 wk
168 wk
192 wk
A6.44 ± 1.396.61 ± 1.285.73 ± 1.256.05 ± 1.20
B6.53 ± 1.246.69 ± 1.125.99 ± 1.476.03 ± 1.49
P0.6540.6960.5330.952
Table 3 Characteristics of seven patients developing genotypic mutations to entecavir

Group A (entecavir)
Group B (entecavir maleate)
Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
Patient 6
Patient 7
Age, yr32342829433421
SexMaleMaleMaleMaleMaleMaleMale
Prior LAM exposureYesYesNoNoYesYesNo
Prior ADV exposureYesYesNoNoYesNoNo
Baseline
HBeAg statusPositive PositivePositivePositivePositivePositivePositive
HBV DNA, log10 IU/mL6.697.998.065.327.777.477.81
LAM resistanceNoNoNoNoNoYesNo
ADV resistanceYesYesNoNoYesNoNo
At maximum viral suppression
wk244872844812120
HBV DNA, log10 IU/mL4.071.182.971.762.264.78TND
At time of resistance confirmed
wk144144144144144144144
HBV DNA, log10 IU/mL6.916.044.411.736.734.961.79
Mutational patternrtL180MrtL180MrtL180MrtL180MrtL180MrtL180MrtL180M
rtS202GrtS202GrtS202GrtV173LrtT184SrtS202GrtT184S
rtM204VrtM204VrtM204VrtM204VrtM204VrtM204VrtM204V
rtM250V
Addition of ADVYesYesYesNoYesYesNo
HBV DNA, log10 IU/mL
Week 1685.145.083.181.843.434.86TND
Week 1924.22.773.1Missing2.894.28Missing